Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05393037 · ClinicalTrials.gov registry record · Phase 3
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)
A Phase 3 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 313
- Enrollment target
NCT05393037 is a Phase 3 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 313 participants.
The verdict
NCT05393037, a Phase 3 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 313 participants
- Enrollment target
Study Summary
This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL V116
- BIOLOGICAL PPSV23
- BIOLOGICAL PCV15
- BIOLOGICAL PCV15 - Part B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2022-07-13 |
| Est. Completion | 2024-01-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05393037
The ClinicalTrials.gov registry entry for NCT05393037 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT05393037 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05393037 about?
NCT05393037 is a clinical study titled "Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7)". This study will evaluate the safety, tolerability, and immunogenicity of a pneumococcal 21-valent conjugate vaccine (V116) in persons living with human immunodeficiency virus (HIV), for the prevention of pneumococcal disease caused by the serotypes in the vaccine.
What is the current status of trial NCT05393037?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 313 participants. The study started on 2022-07-13. Estimated completion is 2024-01-25.
What interventions are being tested in trial NCT05393037?
The interventions under investigation include: Placebo (BIOLOGICAL), V116 (BIOLOGICAL), PPSV23 (BIOLOGICAL), PCV15 (BIOLOGICAL), PCV15 - Part B (BIOLOGICAL).
Who is sponsoring clinical trial NCT05393037?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.